Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Franco Aversa

Showing results (151-160 of 160) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 160 results.
Hematological Oncology|April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patientsNicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Bone Marrow Transplantation|March 6, 2019
The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantationStefan O Ciurea, Monzr M Al Malki, Piyanuch Kongtim, et al.
British Journal of Haematology|July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patientsFrancesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
Annals of Hematology|December 6, 2018
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinibMassimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, et al.
Nature Communications|June 4, 2024
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AMLMatteo Marchesini, Andrea Gherli, Elisa Simoncini, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
Seminars in Hematology|December 4, 2018
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study<sup>⁎</sup>Francesca Palandri, Giuseppe A Palumbo, Alessandra Iurlo, et al.
Haematologica|September 21, 2019
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMTBhagirathbhai Dholaria, Bipin N Savani, Myriam Labopin, et al.
British Journal of Haematology|January 29, 2015
Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registryLivio Pagano, Maria Stamouli, Mario Tumbarello, et al.
Haematologica|February 2, 2015
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)Morena Caira, Anna Candoni, Luisa Verga, et al.
Pageof 16

Showing results (151-160 of 160) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 160 results.
Hematological Oncology|April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patientsNicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Bone Marrow Transplantation|March 6, 2019
The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantationStefan O Ciurea, Monzr M Al Malki, Piyanuch Kongtim, et al.
British Journal of Haematology|July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patientsFrancesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
Annals of Hematology|December 6, 2018
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinibMassimo Breccia, Daniela Bartoletti, Massimiliano Bonifacio, et al.
Nature Communications|June 4, 2024
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AMLMatteo Marchesini, Andrea Gherli, Elisa Simoncini, et al.
Oncotarget|November 8, 2017
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosisFrancesca Palandri, Giuseppe Alberto Palumbo, Massimiliano Bonifacio, et al.
Seminars in Hematology|December 4, 2018
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study<sup>⁎</sup>Francesca Palandri, Giuseppe A Palumbo, Alessandra Iurlo, et al.
Haematologica|September 21, 2019
Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMTBhagirathbhai Dholaria, Bipin N Savani, Myriam Labopin, et al.
British Journal of Haematology|January 29, 2015
Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registryLivio Pagano, Maria Stamouli, Mario Tumbarello, et al.
Haematologica|February 2, 2015
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study)Morena Caira, Anna Candoni, Luisa Verga, et al.
Pageof 16